Stay updated on APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial
Sign up to get notified when there's something new on the APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial page.

Latest updates to the APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedNo significant changes detected; the page content remains the same, with only minor visual differences. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check19 days agoNo Change Detected
- Check41 days agoChange DetectedPage updated to v3.2.0 with a new government-operating status notice; previous version v3.1.0 reference removed. Core content remains, but timing/operational details are updated.SummaryDifference3%

- Check48 days agoChange DetectedThe page mainly updates the version tag to v3.1.0 and removes a prior version tag (v3.0.2); a reference to Dense deposit disease is also removed. No substantive changes to core content, pricing, or key entities are evident.SummaryDifference0.2%

- Check62 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2 and removed the 'Back to Top' link — a small, mostly UI-focused update.SummaryDifference0.2%

- Check69 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check77 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as additional drug information and publications, while removing outdated location terms and certain genetic disease resources.SummaryDifference7%

Stay in the know with updates to APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial page.